M. Maynard-Muet

1.4k total citations
15 papers, 323 citations indexed

About

M. Maynard-Muet is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, M. Maynard-Muet has authored 15 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 10 papers in Epidemiology and 5 papers in Rheumatology. Recurrent topics in M. Maynard-Muet's work include Hepatitis C virus research (12 papers), Liver Disease Diagnosis and Treatment (7 papers) and Hepatitis B Virus Studies (6 papers). M. Maynard-Muet is often cited by papers focused on Hepatitis C virus research (12 papers), Liver Disease Diagnosis and Treatment (7 papers) and Hepatitis B Virus Studies (6 papers). M. Maynard-Muet collaborates with scholars based in France, Canada and Italy. M. Maynard-Muet's co-authors include Jean‐Pierre Zarski, Marie‐Christine Jacob, Vincent Leroy, J Arvieux, Jean–Pierre Bronowicki, Pierre Lebon, C. Trépo, Geneviève Inchauspé, Géraldine Honnet and Cyrille Féray and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

M. Maynard-Muet

15 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Maynard-Muet France 9 220 214 82 33 31 15 323
Maria Grazia Marin Italy 5 320 1.5× 229 1.1× 68 0.8× 66 2.0× 56 1.8× 7 364
T. Gerlach Germany 6 241 1.1× 186 0.9× 35 0.4× 75 2.3× 22 0.7× 12 304
Chiharu Ohue Japan 8 323 1.5× 280 1.3× 45 0.5× 21 0.6× 65 2.1× 10 421
Kurt W. Roth Germany 7 371 1.7× 327 1.5× 83 1.0× 21 0.6× 21 0.7× 8 404
M. Willems Belgium 11 257 1.2× 215 1.0× 37 0.5× 13 0.4× 29 0.9× 12 354
Galia Askarieh Sweden 8 311 1.4× 262 1.2× 85 1.0× 96 2.9× 13 0.4× 11 438
Gaétana Di Liberto France 9 205 0.9× 176 0.8× 32 0.4× 30 0.9× 21 0.7× 15 408
Catherine Gaudy France 9 215 1.0× 181 0.8× 32 0.4× 14 0.4× 26 0.8× 14 270
E Fagan United Kingdom 4 232 1.1× 279 1.3× 35 0.4× 47 1.4× 11 0.4× 7 443
JP Vinel France 6 241 1.1× 194 0.9× 56 0.7× 46 1.4× 14 0.5× 11 312

Countries citing papers authored by M. Maynard-Muet

Since Specialization
Citations

This map shows the geographic impact of M. Maynard-Muet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Maynard-Muet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Maynard-Muet more than expected).

Fields of papers citing papers by M. Maynard-Muet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Maynard-Muet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Maynard-Muet. The network helps show where M. Maynard-Muet may publish in the future.

Co-authorship network of co-authors of M. Maynard-Muet

This figure shows the co-authorship network connecting the top 25 collaborators of M. Maynard-Muet. A scholar is included among the top collaborators of M. Maynard-Muet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Maynard-Muet. M. Maynard-Muet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Maynard-Muet, M., Bérénice Segrestin, Laurent Milot, et al.. (2024). The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD. Obesity. 32(6). 1114–1124. 4 indexed citations
2.
Caussy, Cyrielle, M. Maynard-Muet, Jérôme Dumortier, et al.. (2023). Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics. Diabetes Metabolic Syndrome and Obesity. Volume 16. 1721–1729. 1 indexed citations
3.
Scholtès, Caroline, et al.. (2023). Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019–2021): A case–control study. Journal of Viral Hepatitis. 30(10). 830–833. 2 indexed citations
4.
5.
Boyd, Anders, Lionel Piroth, Sarah Maylin, et al.. (2016). Intensification with pegylated interferon during treatment with tenofovir in HIV–hepatitis B virus co‐infected patients. Journal of Viral Hepatitis. 23(12). 1017–1026. 10 indexed citations
6.
Miailhes, Patrick, M. Maynard-Muet, Fanny Lebossé, et al.. (2014). Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. Journal of Hepatology. 61(4). 761–769. 15 indexed citations
7.
Martínez, Stella Maris, Juliette Foucher, Sophie Métivier, et al.. (2012). Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy. PLoS ONE. 7(10). e47715–e47715. 53 indexed citations
8.
Habersetzer, François, Géraldine Honnet, Christine Bain, et al.. (2011). A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C. Gastroenterology. 141(3). 890–899.e4. 66 indexed citations
9.
Zarski, Jean‐Pierre, Valériane Leroy, M. Maynard-Muet, et al.. (2009). 42 A NOVEL VECTORIZED HCV THERAPEUTIC VACCINE (TG4040): RESULTS OF A PHASE I STUDY IN NAIVE PATIENTS CHRONICALLY INFECTED BY HCV. Journal of Hepatology. 50. S18–S18. 8 indexed citations
10.
Fontanges, Thierry, François Bailly, Eric Trépo, et al.. (2008). Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique. 32(10). 858–865. 12 indexed citations
11.
12.
Leroy, Vincent, et al.. (1998). Prevalence and significance of anticardiolipin, anti‐β2 glycoprotein I and anti‐prothrombin antibodies in chronic hepatitis C. British Journal of Haematology. 101(3). 468–474. 69 indexed citations
13.
Maynard-Muet, M., et al.. (1998). Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. Journal of Hepatology. 28(3). 375–381. 36 indexed citations
14.
Maynard-Muet, M., S. Chousterman, R Barnoud, et al.. (1998). Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology. 27(3). 862–867. 25 indexed citations
15.
Rolachon, A, et al.. (1997). [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].. PubMed. 21(12). 924–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Grazia Marin Breakdown of academic impact, for papers by T. Gerlach Breakdown of academic impact, for papers by Chiharu Ohue Breakdown of academic impact, for papers by Kurt W. Roth Breakdown of academic impact, for papers by M. Willems Breakdown of academic impact, for papers by Galia Askarieh Breakdown of academic impact, for papers by Gaétana Di Liberto Breakdown of academic impact, for papers by Catherine Gaudy Breakdown of academic impact, for papers by E Fagan Breakdown of academic impact, for papers by JP Vinel
Rankless by CCL
2026